| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.AHJ.2009.02.020 |
| P698 | PubMed publication ID | 19376308 |
| P50 | author | Christine Garnett | Q41772806 |
| P2093 | author name string | Yi Tsong | |
| Peter R Kowey | |||
| Ignacio Rodriguez | |||
| Norman Stockbridge | |||
| Richard J Kovacs | |||
| Kathleen Uhl | |||
| Stephen Grant | |||
| Brian P Booth | |||
| Edwin P Rock | |||
| Colette Strnadova | |||
| Shari L Targum | |||
| Wendy R Sanhai | |||
| John Finkle | |||
| Howard J Fingert | |||
| Robert L Justice | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 827-36, 836.e1 | |
| P577 | publication date | 2009-05-01 | |
| P1433 | published in | American Heart Journal | Q2227156 |
| P1476 | title | Assessing proarrhythmic potential of drugs when optimal studies are infeasible | |
| P478 | volume | 157 |
| Q53389879 | A Quantitative Framework to Evaluate Proarrhythmic Risk in a First-in-Human Study to Support Waiver of a Thorough QT Study. |
| Q51301390 | A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. |
| Q40183675 | An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors |
| Q38071134 | Assessing blood pressure responses to noncardiovascular drugs: the beneficial role of ambulatory blood pressure monitoring |
| Q89970820 | Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death |
| Q63363578 | Can laypeople identify a drug-induced QT interval prolongation? A psychophysical and eye-tracking experiment examining the ability of nonexperts to interpret an ECG |
| Q53139178 | Cardiovascular Safety in Drug Development: A Role for Endothelial Function Tests. |
| Q38101883 | Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). |
| Q38082420 | Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated? |
| Q42650229 | Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort. |
| Q27020964 | Early QT assessment--how can our confidence in the data be improved? |
| Q48218548 | Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies |
| Q41582221 | Effect of axitinib on the QT interval in healthy volunteers. |
| Q43657215 | Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study |
| Q37373164 | Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study |
| Q39816545 | Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer |
| Q92444961 | Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis |
| Q37799117 | Electrocardiographic assessment for therapeutic proteins—scientific discussion |
| Q36023863 | Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin |
| Q82243223 | Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval) |
| Q40919417 | Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab |
| Q37302085 | Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters |
| Q46686425 | Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities |
| Q41647458 | Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer |
| Q38351470 | Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities. |
| Q46557749 | PK/PD Modelling of the QT Interval: a Step Towards Defining the Translational Relationship Between In Vitro, Awake Beagle Dogs, and Humans |
| Q96132498 | Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors |
| Q50767775 | Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. |
| Q34207034 | Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy |
| Q33390876 | Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. |
| Q52715040 | Strategic and Statistical Considerations on the QT Assessment of Volasertib. |
| Q53707802 | The Role of Public-Private Partnerships in Catalyzing the Critical Path. |
| Q33661017 | The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance |
| Q37650057 | Thorough QT Studies: Questions and Quandaries |
| Q27001737 | Towards a better understanding of QT interval variability |
| Q24646866 | Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development |
| Q38959783 | hERG1 potassium channel in cancer cells: a tool to reprogram immortality |
Search more.